Associations of polypharmacy with frailty severity and each frailty phenotype in community-dwelling older adults: Itabashi Longitudinal Study on Aging
- PMID: 38169078
- DOI: 10.1111/ggi.14789
Associations of polypharmacy with frailty severity and each frailty phenotype in community-dwelling older adults: Itabashi Longitudinal Study on Aging
Abstract
Aim: Although polypharmacy and frailty are concerns in older adults, there is limited understanding of their association, particularly regarding frailty severity and its phenotypes within this population. This study aimed to examine the association between polypharmacy and frailty severity or frailty phenotypes in community-dwelling older Japanese adults.
Methods: This cross-sectional study included 1021 older adults from the Itabashi Longitudinal Study on Aging. Men accounted for 45.4%, and the mean age (standard deviation) was 77.9 (5.1) years. Participants were classified into frail (n = 67), pre-frail (n = 543), and robust (n = 411) groups using the revised Japanese Cardiovascular Health Study criteria. Polypharmacy was defined as using five or more self-reported prescription drugs. Ordinal and binomial logistic regression analyses examined the association between polypharmacy and frailty severity or frailty phenotypes (weight loss, weakness, exhaustion, slowness, and low activity). These models were adjusted for age, sex, body mass index, number of comorbidities, living status, employment status, years of education, as well as drinking and smoking habits.
Results: The prevalence of frailty in participants with and without polypharmacy was 10.1% and 5.0%, respectively. Participants with polypharmacy were more likely to have frailty (adjusted odds ratio [95% confidence interval], 1.89 [1.40-2.57]), weight loss (1.81 [1.00-3.27]), weakness (1.50 [1.08-2.09]), and slowness (2.25 [1.29-3.94]) compared with the no-polypharmacy group.
Conclusions: Polypharmacy was associated with frailty severity and three frailty phenotypes. Longitudinal studies are required to investigate whether polypharmacy can predict the development and progression of frailty. Geriatr Gerontol Int 2024; 24: 196-201.
Keywords: cross‐sectional study; frailty; older adults; phenotype; polypharmacy.
© 2024 Japan Geriatrics Society.
Similar articles
-
Polypharmacy is associated with frailty in Japanese community-dwelling older adults.Geriatr Gerontol Int. 2018 Oct;18(10):1497-1500. doi: 10.1111/ggi.13507. Epub 2018 Aug 30. Geriatr Gerontol Int. 2018. PMID: 30168240
-
Association of potentially inappropriate medications with frailty and frailty components in community-dwelling older women in Japan: The Otassha Study.Geriatr Gerontol Int. 2025 May;25(5):686-693. doi: 10.1111/ggi.70035. Epub 2025 Mar 21. Geriatr Gerontol Int. 2025. PMID: 40119543
-
Number of medications and polypharmacy are associated with frailty in older adults: results from the Midlife in the United States study.Front Public Health. 2023 May 25;11:1148671. doi: 10.3389/fpubh.2023.1148671. eCollection 2023. Front Public Health. 2023. PMID: 37304087 Free PMC article.
-
Longitudinal association between eating alone and deterioration in frailty status: The Korean Frailty and Aging Cohort Study.Exp Gerontol. 2023 Feb;172:112078. doi: 10.1016/j.exger.2022.112078. Epub 2022 Dec 28. Exp Gerontol. 2023. PMID: 36584805 Review.
-
Scoping Review of Studies Evaluating Frailty and Its Association with Medication Harm.Drugs Aging. 2022 May;39(5):333-353. doi: 10.1007/s40266-022-00940-3. Epub 2022 May 22. Drugs Aging. 2022. PMID: 35597861 Free PMC article.
Cited by
-
A narrative review of interventions for post-stroke frailty: current advances and future directions.Front Neurol. 2025 Jul 8;16:1592797. doi: 10.3389/fneur.2025.1592797. eCollection 2025. Front Neurol. 2025. PMID: 40697579 Free PMC article. Review.
References
-
- World Health Organization. Ageing and health [Internet]. 1 October 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health.
-
- Fried LP, Tangen CM, Walston J et al. Cardiovascular health study collaborative research group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146–M157.
-
- Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet 2019; 394: 1365–1375.
-
- World Health Organization. Medication Safety in Polypharmacy [Internet]. The WHO Document Production Services, Geneva, Switzerland. 2019. Available from: https://www.who.int/docs/default-source/patient-safety/who-uhc-sds-2019-...
-
- Kojima T, Mizokami F, Akishita M. Geriatric management of older patients with multimorbidity. Geriatr Gerontol Int 2020; 20: 1105–1111.
MeSH terms
LinkOut - more resources
Full Text Sources